Last reviewed · How we verify
Motilium (domperidone)
Domperidone (Motilium) is a peripheral dopamine antagonist prokinetic developed by Janssen. Widely available globally but NOT approved in the US. Preferred over metoclopramide for avoiding CNS side effects.
At a glance
| Generic name | domperidone |
|---|---|
| Also known as | Motilium |
| Sponsor | Johnson & Johnson (Janssen) |
| Drug class | Prokinetic agent / Antiemetic |
| Target | Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1978-01-01 (Belgium) |
Approved indications
- Nausea and vomiting
Common side effects
Key clinical trials
- Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants (Phase 4)
- Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial (Phase 4)
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention o (Phase 3)
- A Randomized, Placebo- and Positive-Controlled, Multiple-Dose, 4-Way Crossover Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Subjects (Phase 1)
- Pragmatic Clinical Trials in Scleroderma (NA)
- Randomized Controlled Trial of Apomorphine in Severe Brain-injured Patients: a Double-blind Behavioral and Neuroimaging Study (Phase 2)
- MONITORING OF REALITY AND DOPAMINE: A PHARMACOLOGICAL RESEARCH (NA)
- A Double Blind Placebo Controlled Trial Examining the Effect of Domperidone on the Composition of Breast Milk (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |